Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With CKD
NCT03992066Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by Akebia Therapeutics. Primary endpoints: Mean area under concentration-time curve from time 0 to the last quantifiable concentration (AUClast) at Day 10, Area under concentration-time curve from time 0 to infinity (AUCinf) at Day 10 and 7 more. Started May 2019; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03992066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992066.